Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Medscape Education’s Large Presence at IDWeek 2023

Medscape are powering education and disease state awareness in infectious diseases at #IDWeek 2023

Medscape Education

- PMLiVE

WHO recommends second malaria vaccine for children

The addition of R21/Matrix-M to the organisation’s list is expected to result in sufficient malaria vaccine supply

- PMLiVE

NFID and CDC urge US adults to get vaccinated against flu and COVID-19

A survey revealed that more than 40% of US adults may not get vaccinated this autumn and winter

- PMLiVE

Sanofi enters agreement with Janssen to develop E. coli vaccine candidate

Extraintestinal pathogenic E. coli is a leading cause of sepsis, particularly in older adults

- PMLiVE

Man vs microbe: the fight against antimicrobial resistance

How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics

- PMLiVE

Dollo’s law

Why you and your company may be worse, rather than better, than you used to be

- PMLiVE

Nobel Prize in Medicine awarded to pair of scientists behind mRNA COVID-19 vaccines

Katalin Karikó and Drew Weissman’s findings paved the way for effective mRNA vaccines

A female clinical using her smartphone wearing blue scrubs

Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital

Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...

Graphite Digital

- PMLiVE

HOW TO TRANSFORM YOUR HEALTHCARE BRAND MARKETING FROM MULTI-CHANNEL TO OMNICHANNEL

In a previous blog, we outlined the role of omnichannel in healthcare and the importance of personalised communications with the suggestion of using modular content to support an omnichannel approach.  No...

IGNIFI

Biogen Idec building

Biogen’s Actemra biosimilar approved by FDA to treat adult and paediatric arthritis

Tofidence is now the first biosimilar referencing Actemra to gain approval from the US regulator

regeneron headquarters

Regeneron’s odronextamab granted FDA priority review for non-Hodgkin lymphoma

The regulator is expected to make a decision on the drug by the end of March 2024

- PMLiVE

The impact of prostate cancer on global health

Noel Clarke talks to PME about current research for prostate cancer and how treatments have improved over the last decade

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links